Hyphens Pharma licenses Nabota® for use in Malaysia and Singapore

Feb & Aug 2023 – We are pleased to bring Nabota® to Malaysian and Singapore markets. A premium high-purity botulinum toxin A (BTA) formulated from our partner Daewoong Pharmaceutical’s patented Hi-PureTM technology, Nabota® is characterised by its high safety, rapid effect, and uniform spreading power. It is the first Asian BTA approved by the U.S. Food and Drug Administration, with over 1 million treatments performed in the United States since 2019.

The release as fetched from its publisher. com.sg ↗